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Abstract
Background: For gastric cancer patients, surgical resection with en-bloc lymphadenectomy is the cornerstone of
curative treatment. Open gastrectomy has long been the preferred surgical approach worldwide. However, this
procedure is associated with considerable morbidity. Several meta-analyses have shown an advantage in short-term
outcomes of laparoscopic gastrectomy compared to open procedures, with similar oncologic outcomes. However,
it remains unclear whether the results of these Asian studies can be extrapolated to the Western population. In this
trial from the Netherlands, patients with resectable gastric cancer will be randomized to laparoscopic or open
gastrectomy.
Methods: The study is a non-blinded, multicenter, prospectively randomized controlled superiority trial. Patients
(≥18 years) with histologically proven, surgically resectable (cT1-4a, N0-3b, M0) gastric adenocarcinoma and
European Clinical Oncology Group performance status 0, 1 or 2 are eligible to participate in the study after
obtaining informed consent. Patients (n = 210) will be included in one of the ten participating Dutch centers and
are randomized to either laparoscopic or open gastrectomy. The primary outcome is postoperative hospital stay
(days). Secondary outcome parameters include postoperative morbidity and mortality, oncologic outcomes,
readmissions, quality of life and cost-effectiveness.
Discussion: In this randomized controlled trial laparoscopic and open gastrectomy are compared in patients with
resectable gastric cancer. It is expected that laparoscopic gastrectomy will result in a faster recovery of the patient
and a shorter hospital stay. Secondly, it is expected that laparoscopic gastrectomy will be associated with a lower
postoperative morbidity, less readmissions, higher cost-effectiveness, better postoperative quality of life, but with
similar mortality and oncologic outcomes, compared to open gastrectomy. The study started on 1 December 2014.
Inclusion and follow-up will take 3 and 5 years respectively. Short-term results will be analyzed and published after
discharge of the last randomized patient.
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Background
Gastric cancer is the fifth most prevalent cancer and the
third most common cause of cancer related death world-
wide [1]. Surgical resection with en-bloc lymphadenec-
tomy is the cornerstone of curative treatment, however
only half of the patients are eligible for surgery with
curative intent. The 5-year survival rate after curative re-
section is 45 % [2]. Perioperative chemotherapy im-
proves 5-year survival with approximately 10 % [3, 4].
Open gastrectomy is the preferred surgical approach
worldwide [5]. However, this procedure is associated
with considerable morbidity [6–8]. Minimally invasive
gastrectomy was introduced in 1993 and aimed at redu-
cing surgical trauma and as a consequence lowering
morbidity and mortality [9]. Several systematic reviews
and meta-analyses have shown an advantage in short-
term outcomes of laparoscopic distal and total gastrec-
tomy compared to open procedures. Oncologic out-
comes are similar on the short term [7, 8, 10–12].
However, these studies are mainly performed in the
Asian population in which early gastric cancer is de-
tected at a higher rate due to a screening program. This
is in contrast to the Western population in which gastric
carcinoma is usually diagnosed at an advanced stage
[13]. Furthermore, the Western patients are older and
have a different spectrum of comorbidities compared to
the Asian population [14]. Therefore, it remains unclear
whether the results of these Asian studies can be extrap-
olated to the Western population.
This protocol describes a multicenter, prospectively,
randomized controlled trial comparing laparoscopic versus
open gastrectomy for gastric cancer in the Netherlands,
entitled Laparoscopic versus Open Gastrectomy for gastrIc
CAncer (LOGICA-trial).
Aim of the study
The aim of this multicenter, prospectively randomized
controlled superiority trial is to compare laparoscopic
gastrectomy versus open gastrectomy in patients with
resectable gastric adenocarcinoma. The primary out-
come parameter is postoperative hospital stay. Secondary
outcome parameters are postoperative morbidity and




The objective of this study is to compare laparoscopic
versus open gastrectomy in patients with resectable
gastric adenocarcinoma by means of a randomized con-
trolled trial. The primary outcome parameter is postop-
erative hospital stay in days. Secondary outcome
parameters are postoperative morbidity and mortality,
oncologic outcomes, readmissions, quality of life and
cost-effectiveness. It is hypothesized that laparoscopic
gastrectomy leads to shorter hospital stay, lower postop-
erative morbidity, less readmissions, higher cost-
effectiveness, higher postoperative quality of life, and
more patients fit for postoperative chemotherapy, with
similar mortality and oncologic outcomes compared to
the current standard of care, i.e. open gastrectomy.
Study design
This is a non-blinded multicenter prospectively random-
ized controlled, superiority trial comparing laparoscopic
versus open gastrectomy in patients with resectable gas-
tric adenocarcinoma. This study is conducted in accord-
ance with the principles of the Declaration of Helsinki
and Good Clinical Practice Guidelines. The independent
ethics committee of the University Medical Center
Utrecht (UMC Utrecht) has approved this study for
all participating sites. Written informed consent will
be obtained from all participating patients. Clinical
trial monitoring will be conducted by an independent
monitor. A Data Safety Monitoring Board (DSMB) is
appointed to evaluate the trial by interim analysis.
Study population
Patients (≥18 years) with histologically proven, surgically
resectable (cT1-4a, N0-3b, M0) gastric adenocarcinoma
are eligible to participate in the study. Patients should
have performance status 0, 1 or 2 according to the Euro-
pean Clinical Oncology Group (ECOG). Written informed
consent is required.
Patients’ inclusion and exclusion criteria are defined as
follows:
Inclusion criteria:
 Histologically proven adenocarcinoma of the
stomach
 Surgically resectable (cT1-4a, N0-3b, M0) tumor
 Age ≥ 18 years
 ECOG performance status 0,1 or 2.
 Written informed consent
Exclusion criteria
 Siewert type I tumor (tumor located between 1 and
5 cm proximal from the esophago-gastric junction)
 Pregnancy
Study protocol
Patients will be informed and included at the surgical
outpatient department at one of the following ten Dutch
investigational centers: University Medical Center Utrecht,
Utrecht; Academic Medical Center, Amsterdam; Catharina
Hospital, Eindhoven; Erasmus Medical Center, Rotterdam;
Leiden University Medical Center, Leiden; Zuyderland
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MC, Sittard; Rijnstate Hospital, Arnhem; VU University
Medical Center, Amsterdam; ZGT Hospital, Almelo; Me-
ander Medical Center, Amersfoort.
The performance status (ECOG) of the patients is
assessed. The Dutch guideline on gastric cancer will be
used to guide preoperative diagnostic measurements
[15]. According to this guideline, all included patients
will undergo gastro-esophagoscopy with biopsy and
computed tomography of the thorax and abdomen to
identify metastatic disease and the extension of the dis-
ease before inclusion.
Patients will receive perioperative chemotherapy ac-
cording to current Dutch guidelines for gastric cancer
[15]. After signing informed consent, the study coordin-
ator will directly randomize participants by means of an
online random treatment generator (Fig. 1), stratified by
center and type of resection (distal or total gastrectomy).
The surgeon, patient and coordinating researcher are
not blinded for the allocated treatment. However, the
data-analyst will be blinded for the allocated procedure
(Fig. 1).
Blood samples will be obtained before surgery, directly
postoperatively and on postoperative day two to monitor
CRP and leukocyte count to obtain an indication of early
inflammatory response after surgery.
The study started on 1 December 2014. Inclusion and
follow-up will take 3 and 5 years respectively. The total
duration of the study will be 8 years. Study participants
can leave the study at any time, for any reason, without
any consequences. Study participants will be replaced by
newly recruited and randomized subjects in case of
withdrawal before surgery. Analysis will be on an
intention to treat basis.
Total gastrectomy
The patient is positioned in supine position under gen-
eral anesthesia. The conventional open total gastrectomy
is performed by means of an upper midline laparotomy.
In case of the laparoscopic procedure, the number and
placement of the camera, working and assistance ports
will be performed according to the surgeons’ preference.
After establishment of pneumoperitoneum and intro-
duction of the camera port, the working ports and assist-
ance ports are introduced under direct vision.
In both procedures, first the lesser omentum is di-
vided. Next, the lesser and greater curvatures of the
stomach are dissected together with the locoregional
lymph nodes. The left gastric artery and vein are trans-
ected at their origin. Next, the right gastroepiploic artery
and the right gastric artery are transected at their origin.
The duodenum is divided at least 1 cm distal to the pyl-
oric sphincter by means of an endostapler. Subsequently,
the distal esophagus is dissected from the left and right
crus and mobilized, after which the distal esophagus is
transected with an endostapler. Frozen section histology
is performed to assess the extent of tumor invasion at
the resection planes when indicated. The greater omen-
tum is resected separately or en-bloc and marked uni-
formly. In the laparoscopic procedure the removal of the
resected specimen with en-bloc lymphadenectomy and
the greater omentum occurs via a mini-laparotomy
(max. 5–6 cm), which must be muscle sparing. Next, an
esophago-jejunostomy is performed by means of a
Roux-en-Y reconstruction. The formation of a jejunal
pouch and a feeding jejunostomy is optional [16, 17].
Distal gastrectomy
The conventional open distal gastrectomy is performed
by means of a midline laparotomy. In case of the laparo-
scopic procedure, the number and placement of the
camera, working and assistance ports will be performed
according to the surgeons’ preference. In both proce-
dures, the lesser omentum is opened. Next, the greater
curvature of the stomach is prepared. The left gastric ar-
tery and vein are transected at their origin. The gastrocolic
ligament is divided at 3 cm distal to the gastroepiploic ar-
tery, after which the greater curvature is skeletonized up
to the gastrosplenic ligament. The right gastroepiploic
vein and artery are transected at its origin. Next the right
gastric vessels are transected. The duodenum is divided
distal to the pyloric sphincter by means of an endostapler.
The proximal side of the stomach is divided at least 6 cm
cranially from the tumor. Frozen section histology is per-
formed to assess the extent of tumor invasion at the distal
Fig. 1 LOGICA-trial flowchart
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resection plane. Resection of the greater omentum is per-
formed separately or en-bloc and marked uniformly. In
the laparoscopic procedure, the removal of the resected
specimen with en-bloc lymphadenectomy and omentum
occurs via a mini-laparotomy (max. 5–6 cm), which must
be muscle sparing. Finally, a gastro-jejunostomy is per-
formed with Roux-en-Y reconstruction [18, 19].
Lymphadenectomy
Lymph node dissection is performed according to the
Dutch oncologic guidelines and Japanese gastric cancer
treatment guidelines [5, 20, 21]. For D2 lymphadenec-
tomy no pancreatico-splenectomy is performed since
this is associated with high postoperative morbidity and
mortality without proven benefit [2]. Furthermore,
lymph node station ten is not dissected during total gas-
trectomy since it has no additive oncological value and
is associated with morbidity [2, 20]. Lymph node stations
1–3, 4d, 4sa, 4sb, 5–9, 11p, 11d and 12a are dissected
during total gastrectomy. Lymph node stations 1, 3, 4d,
4sb, 5–9, 11p and 12a are dissected during distal gas-
trectomy (Fig. 2).
Surgical and pathological quality control
All procedures will be carried out in one of the 10 par-
ticipating centers. To ensure quality and minimize differ-
ences between the laparoscopic procedures, all surgeons
have participated in the course “One day course on min-
imally invasive gastrectomy”, which is organized by the
UMC Utrecht. All surgeons completed their learning
curves (n ≥ 20) for laparoscopic gastrectomy. The cen-
ters can start with inclusion after one of the proctors
(RvH or JR) has supervised at least two laparoscopic
procedures on site or has reviewed at least two videos of
laparoscopic gastrectomy in which predefined standards
for laparoscopic gastrectomy have been met [22]. All
laparoscopic operations will be recorded on video for
quality control.
To ensure pathological quality, the surgical team will
separately mark the resected specimen for the location
of N1 lymph node stations and resection planes. The N2
lymph node will be dissected and provided in separate
containers. Pathological evaluation will be performed by
an experienced pathologist in each center and will be
reviewed by a central pathologist in the UMC Utrecht.
Pathological evaluation will be performed using a stand-
ard protocol and a checklist, developed by a central co-
ordinating pathologist from the UMC Utrecht and
including tumor characteristics, radicality, number and
location of lymph nodes harvested.
Postoperative treatment
To ensure fast recovery, the Enhanced Recovery After
Surgery (ERAS) Society protocol is followed [16].
Mobilization under supervision starts immediately. On
postoperative day 1, liquid oral feeding can be initiated.
The postoperative treatment does not differ between
both treatment arms, except for epidural analgesia,
which can be initiated after open procedures. Besides an
epidural, other analgesia can be given according to the
local hospital’s preference and will be registered.
Outcome measurements
Laparoscopic gastrectomy is expected to be equivalent
to open gastrectomy in terms of short-term oncologic
outcomes, such as R0-resection rate and number of
lymph nodes harvested, but to result in less surgical
trauma. The primary outcome of this study is length of
postoperative hospital stay. Criteria for discharge are
those for functional recovery and include: started with
mobilization, oral or enteral intake according to nutri-
tional demand, without supplementary intravenous fluids
and adequate pain control with oral medication.
Secondary outcome measurements include postoperative
morbidity and mortality, readmissions, cost-effectiveness,
oncologic outcome and quality of life. Standardized def-
initions will be used for complications and include anas-
tomotic leakage, anastomotic stricture and number of
dilatations, respiratory complications, cardiac complica-
tions, chyle leakage, intra-abdominal bleeding, intra-
Fig. 2 Gastric lymph nodes
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abdominal abscess and wound infection [23]. All compli-
cations will be classified according to the Clavien-Dindo
system [24]. Oncologic outcome will be measured by R0
resection rate and the number of lymph nodes resected.
The validated quality of life questionnaires Euro Quality
of Life-5D-5 L (EQ-5D-5 L), European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire 30 (EORTC QLQ-30) and the Stomach
22 module (EORTC QLQ-STO22) will be filled in pre-
operative and postoperative at 6 weeks, 6, 12, 24, 36, 48
and 60 months after surgery [25–27]. Costs will be
based on the recorded volumes and unit costs associ-
ated with both procedures, including costs of hospital
and ICU stay, costs of operating rooms and costs associ-
ated with complications and reoperations. Effect will be
based on the quality of life and productivity of patients.
Productivity will be measured with the Short Form
Health and Labour Questionnaire (SF-HLQ) [28].
Other study parameters include baseline characteris-
tics (gender, age, American Society of Anesthesiologists
(ASA) classifications, BMI, comorbidities, perioperative
chemotherapy), peri-operative outcomes (blood loss,
duration of surgery, conversion rate), survival (overall
and disease free), patients experience (Visual Analogue
Scale ;VAS) for pain, time to return to normal nutrition
regime and time to return to daily activity) and weight.
Surgeons’ ergonomics are measured by means of the
Subjective Mental Effort Questionnaire (SMEQ) [29].
Sample size calculation
The primary outcome parameter is length of postopera-
tive hospital stay. The hypothesis is that laparoscopic
gastrectomy will result in a shorter postoperative hos-
pital stay compared with open gastrectomy. A recent
meta-analysis showed that a laparoscopic procedure
shortened the median hospital stay from 18 to 14 days
[7]. It was calculated (α = 0.05, Power = 0.80) that 210
patients (105 in each treatment arm) are required to de-
tect this 4-day reduction in postoperative hospital stay.
Statistical analysis
Analysis will take place using SPSS statistical software
(SPSS Inc. Chicago, Illinois, USA) and R statistical com-
puting (R Foundation for Statistical Computing, Vienna,
Austria). Data analysis will be performed on an
intention-to-treat basis. Additional per-protocol analysis
will be performed for tumor type, tumor stage and type
of gastrectomy (distal versus total).
Differences in improvement in primary and secondary
outcomes between interventions are analyzed using linear
mixed-effects modeling or longitudinal Poisson regression,
taking relevant patient characteristics into account [30].
Missing values will be imputed using multiple imput-
ation techniques. Kaplan-Meier survival curves will be
computed to evaluate differences in disease-free and
overall survival. Log-rank tests will be used to compare
survival curves and the Cox regression model will be
used to accomplish multivariate analysis.
Cost-effectiveness will be calculated by comparing
costs and effects in relation to both strategies up until
one year after the operation. A societal perspective will
be used for this analysis, i.e. medical and non-medical
direct and indirect costs will be taken into account.
After analyzing mean costs and effects for both strat-
egies an incremental cost-effectiveness ratio will be cal-
culated. Results will be presented using incremental
cost-effectiveness planes and cost-effectiveness accept-
ability curves. Costs and effects will be discounted ac-
cording to Dutch guidelines. Bootstrapping will be used
to assess uncertainty in the balance between costs and
effects.
Interim analysis
Outcomes will be evaluated by the DSMB after 105 pa-
tients are included, using the Peto approach (p < 0.001).
Stop-criteria are: <70 % R0-resections in one of the
study arms and <50 % of 10 harvested lymph nodes in
one of the study arms. If the DSMB suspects any adverse
effects, a meeting will be organized between the DSMB,
the trial research group and an independent statistician.
The final decision is made by the DSMB. Their opinion
is sent to the study coordinator and principal investiga-
tor. A copy of their advice will be sent to the ethics com-
mittee. The trial will not be stopped for futility (no
difference in postoperative hospital stay between surgical
procedures) as the outcome of all endpoints of this ran-
domized controlled trial on this subject are relevant to
healthcare professionals involved with these procedures
in Western hospitals.
Discussion
The LOGICA-trial is a non-blinded, multicenter, pro-
spectively randomized controlled trial, comparing lap-
aroscopic versus open gastrectomy, which is the gold
standard in patients with resectable gastric adenocarcin-
oma. In the revised 2010 Japanese gastric cancer treat-
ment guidelines, open gastrectomy is considered the
first-choice procedure for patients with resectable gastric
carcinoma [5]. However, this procedure is associated
with considerable morbidity [6].
Minimally invasive techniques have shown to improve
perioperative outcomes in other procedures such as colec-
tomy for colonic cancer and esophagectomy for esopha-
geal carcinoma [31, 32]. For gastrectomy, studies from
Asian populations have shown a benefit for the patient
after laparoscopic gastrectomy compared to open gastrec-
tomy [7, 8, 10–12]. Laparoscopic gastrectomy was associ-
ated with lower intraoperative blood loss, reduced risk of
Haverkamp et al. BMC Cancer  (2015) 15:556 Page 5 of 7
postoperative complications and shorter hospital stay. Re-
section margin, lymph node retrieval and 5-year survival
rate were comparable. This was at the cost of longer op-
erative time [7, 8, 10–12]. However, Western populations
have a more advanced stage tumor, that is located more
frequently in the proximal stomach and diagnosed more
often at an older age compared with the Asian population.
Therefore, it is unknown whether the results of these
studies can be extrapolated to the Western population
[13, 14]. Furthermore, this trial can be used to evaluate
the laparoscopic techniques used.
In the last decennium, laparoscopic gastrectomy has
been introduced in several centers in the Netherlands.
To evaluate this technique, a randomized trial is needed.
Conclusion
This is a randomized controlled trial comparing laparo-
scopic gastrectomy with the gold standard open gastrec-
tomy for surgically resectable gastric carcinoma in a
Western population. It is hypothesized that laparoscopic
gastrectomy will result in a shorter postoperative hospital
stay, lower postoperative morbidity, less readmissions,
higher cost-effectiveness, better postoperative quality of
life, with similar mortality and oncologic outcomes, com-
pared to open gastrectomy.
Trial status
The independent ethics committee of the UMC Utrecht
(NL47444.041.14) approved the trial protocol. Recruitment
of patients started in December 2014.
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